Raymond James Sticks to Their Buy Rating for Acceleron Pharma (XLRN)

Raymond James analyst Danielle Brill maintained a Buy rating on Acceleron Pharma (XLRN) today and set a price target of $155.00. The company’s shares closed last Thursday at $109.49.

According to TipRanks.com, Brill is a 5-star analyst with an average return of 24.0% and a 64.2% success rate. Brill covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, ACADIA Pharmaceuticals, and Sarepta Therapeutics.

Acceleron Pharma has an analyst consensus of Strong Buy, with a price target consensus of $131.14, implying a 16.2% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $148.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $124.01 and a one-year low of $40.15. Currently, Acceleron Pharma has an average volume of 372.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.